5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Kopran Ltd.

•
kopran.comBSE: 524280NSE: KOPRAN
Market Cap₹ 1,137 Cr.
Current Price
High / Low₹ 254 / 107
Stock P/E45.5
Book Value₹ 111
Price to Book0.99
Dividend Yield1.27 %
ROCE6.6 %
ROE4.9 %
Face Value₹ 10

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2026 • Bulk Drugs: 55.3% • Tablet / Capsules / Liquids: 44.3% • Others: 0.5%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company has consistently been profitable over the last 5 years
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.32x)
  • Company has been maintaining a healthy dividend payout of 56.3%
  • Working capital cycle has improved - days down from 128 to 95
  • Company has a consistent dividend-paying track record
  • Company maintains a comfortable, low leverage position

CONS

  • Recent results are weak - TTM profit is down 27.1% versus prior year
  • Company has a low return on equity of 7.8% over last 3 years
  • Company has a low return on capital employed of 10.1%
  • Company has delivered a poor profit growth of -16.0% over past five years
  • Valuation is stretched - P/E of 45.5 is well above its own 5-year median (21.9)
  • Company has delivered a poor sales growth of 6.7% over past five years

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.KOPRAN235.5545.521137.371.276.70-10.04153.9913.886.6510.26
Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
117153159186139152166172135118194234154
111130135164121137146155121123177201147
Operating Profit62324221815201714-518337
OPM %5.39%14.96%14.84%11.66%13.03%9.73%11.93%9.91%10.45%-4.48%9.14%14.08%4.38%
20210310330002
Interest2223222332333
Depreciation3334444444456
Profit before Tax41821251510141410-1211259
Tax %23.27%24.55%22.96%26.05%24.71%23.44%24.96%29.39%24.67%14.62%13.12%25.56%23.88%
Net Profit000011710107-109197
0.582.863.283.862.301.532.162.001.54-2.061.933.911.39

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
310313358359492478551615630681700
274284312313410390499540557619648
Operating Profit3629454782875274736252
OPM %11.66%9.27%12.69%12.99%16.59%18.27%9.40%12.10%11.58%9.09%7.45%
1111401811315402
Interest14999656991011
Depreciation8991010111313161719
Profit before Tax2523322883823668523433
Tax %19.58%10.48%24.13%25.68%26.07%25.37%24.49%24.56%25.79%25.10%24.92%
Net Profit2020242162612751392625
EPS0.000.000.000.0014.2413.775.6510.577.985.33—
Dividend Payout %0.00%0.00%0.00%0.00%10.53%23.70%53.11%28.38%37.57%56.30%—

COMPOUNDED SALES GROWTH

10 Years:
9%
5 Years:
7%
3 Years:
7%

COMPOUNDED PROFIT GROWTH

10 Years:
9%
5 Years:
-16%
3 Years:
-2%

STOCK PRICE CAGR

10 Years:
16%
5 Years:
2%
3 Years:
3%
1 Year:
31%

RETURN ON EQUITY

10 Years:
14%
5 Years:
10%
3 Years:
8%
Last Year:
5%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Corporate actions

2026

Aug 11

₹ 0.30

Rs.3.0000 per share(30%)Final Dividend

2025

Sep 4

₹ 0.30

Rs.3.0000 per share(30%)Final Dividend

2024

Sep 2

₹ 0.30

Rs.3.0000 per share(30%)Final Dividend

2023

Sep 7

₹ 0.30

Rs.3.0000 per share(30%)Dividend

2022

Aug 4

₹ 0.30

Rs.3.0000 per share(30%)Final Dividend

2021

Aug 5

₹ 0.15

Rs.1.5000 per share(15%)Final Dividend

2020

Nov 5

₹ 0.15

Interim Dividend

2026

Jul 17

₹ 0.30

Rs.3.0000 per share(30%)Final Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital43434343434848484848
81101125146202378391442468481
8982877864727398146150
Trade Payables47615155866287113119158
33244348445050426271
Total Liabilities293312349370439611650743844908
104104113111112151165182208346
Capital Work in Progress57172237285678992
61717388100150131138169164
0000000212215263
Cash & Bank76457571314267
117123142144183226286119126125
Total Assets293312349370439611650743844908

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
1729293976-1547434267
Cash from Investing-18-11-25-13-25-84-13-44-56-65
Cash from Financing2-15-1-18-35123-20126-21
-0-0-00052111-19

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
44.4944.4944.4644.4244.4244.4244.4244.4244.42
0.681.310.861.110.760.600.360.570.51
0.140.220.000.000.000.000.000.000.00
Government0.000.000.000.000.000.000.000.000.00
54.7053.9754.6854.4554.8254.9855.2255.0055.06

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-01
Spurt in Volume

2026-09-01 - Significant increase in volume has been observed in Kopran Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Kopran Limited has submitted their response.

2026-08-31
Spurt in Volume

2026-08-31 - Significant increase in volume has been observed in Kopran Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.

2026-08-18
Shareholders meeting

2026-08-18 - Proceedings of AGM, Voting result and Scrutiniser's report.

2026-08-10
Copy of Newspaper Publication

2026-08-10 - Kopran Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-07
Investor Presentation

2026-08-07 - Kopran Limited has informed the Exchange about Investor Presentation

2026-08-07
Outcome of Board Meeting

2026-08-07 - Kopran Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

2026-07-20
Copy of Newspaper Publication

2026-07-20 - Kopran Limited has informed the Exchange about Copy of Newspaper Publication

2026-07-16
Record Date

2026-07-16 - Kopran Limited has informed the Exchange that Record date for the purpose of Dividend is 11-Aug-2026.

2026-07-09
Certificate under SEBI (Depositories and Participants) Regulations, 2018

2026-07-09 - Kopran Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

News

Recent coverage and analyst commentary for KOPRAN

Loading news…

🤖

AI Stock Analyst

Kopran Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login